Objective This study was performed to compare in real-life conditions the serum profile of insulin lispro (IL) after a subcutaneous (SC) injection, separate and mixed with insulin glargine (IG), using a sensitive radioimmunoassay for the specific determination of serum IL, and to evaluate the 12-wk effect of the mixture on glycemic control in young individuals with type 1 diabetes.
Research design and methods The IL serum profiles were evaluated in 10 individuals with type 1 diabetes [age 21.9 ± 3.8 yr; diabetes duration 13.4 ± 4.9 yr; body mass index 25.1 ± 3.2 kg/m2; hemoglobin A1c (HbA1c) 8.3 ± 0.8%] during a mixed meal test (MMT) using IL and IG as separate (baseline) and mixed injection. The glycemic variability by continuous glucose monitoring system (CGMS) and the long-term diabetes control with HbA1c were also evaluated at baseline and after 12 wk mixing the two insulins.
Results The mixture of IL with IG decreased IL maximum serum concentration (CmaxIL) (29.4 ± 5.1 µU/mL vs. 13.7 ± 4.2 µU/mL; p = 0.03) without changing the time to reach the Cmax (TmaxIL), the IL area under the curve (AUCIL0-240), and the glucose dynamics during the MMT. The glucose variability and the HbA1c were equivalent to baseline after 12 wk mixing both insulins.
Conclusions These data suggest that mixing IL with IG immediately before the SC injection decreases IL serum peak concentration without affecting the glycemic profile after 12 wk in this group with type 1 diabetes mellitus.
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market? Lisa S. Rotenstein, BA, Nina Ran, BA, Joseph P. Shivers, BA, Mark Yarchoan, MD and Kelly L. Close, MBA
Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulins have the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes. However, they will have to overcome numerous regulatory hurdles, meet a variety of commercial demands, and effectively confront competition from both established and next-generation branded insulin products before they can succeed on the global market.....
...From 1968–1969 to 2008–2009, the death rate from diabetes among youths aged ≤19 years decreased 61%, from 2.69 per million to 1.05 per million (Table). The death rate among youths aged <10 years decreased 78%, from 1.80 per million to 0.39 per million, and the death rate among youths aged 10–19 years decreased 52%, from 3.56 per million to 1.71 per million.
The trends for diabetes death rates for youths aged <10 years and youths aged 10–19 years indicate different patterns of decrease (Figure). For youths aged <10 years, a steady decrease in diabetes death rates was observed from 1968 to 1995, with an APC of -5.7 (CI = -6.6 to -4.7). However, from 1995 to 2009, the APC was -0.3 (CI = -3.5 to 4.3). For youths aged 10–19 years, a decrease in diabetes death rates occurred from 1968 to 1984, with an APC of -6.5 (CI = -7.9 to -5.1), followed by an increase in rates with an APC of 1.6 (CI = 0.8 to 2.4) from 1984 to 2009....
Although the FDA first approved personal CGM over a decade ago (Cygnus’ GlucoWatch in 2001), a new device for personal use has not been approved since Dexcom’s Seven Plus in 2009. Encouragingly, the FDA ended the dry spell in October by approving Dexcom’s new G4 Platinum CGM system (the “G4” stands for fourth generation, since this product follows the STS, Seven, and Seven Plus). With Kelly and Adam’s (many!) combined years of experience using the Seven Plus (a great product in its own right), what follows is our early take on our favorite improvements in the G4 Platinum, namely in 1) improved accuracy and reliability; 2) a sleeker receiver design; and 3) an extended transmission range....
Abstract: Background: Porcine islet transplantation is emerging as an attractive option for the treatment of patients with type 1 diabetes, with the possibility of providing islets of higher and more consistent quality and in larger volumes than available from human pancreata. The use of encapsulated neonatal porcine islets (ENPI) is appealing because it can address islet supply limitations while reducing the need for anti-rejection therapy. Pre-transplant characterization of ENPI viability and potency is an essential component of the production process. We applied the validated assay for oxygen consumption rate normalized for DNA content (OCR/DNA) to characterize ENPI viability.
Methods: ENPI of low viscosity and high m alginate were prepared according to standard methods and characterized at various culture time points up to 5 weeks.
Results: The OCR/DNA (nmol/min·mgDNA ± SEM) of ENPI (235 ± 10, n = 9) was comparable to that of free NPI (255 ± 14, n = 13). After encapsulation, NPI OCR/DNA was sustained over a culture period of up to 5 weeks. The average OCR/DNA of ENPI cultured longer than 9 days was higher than that of freshly encapsulated NPI.
Conclusion: This is the first characterization of ENPI by a validated and more sensitive method for product viability. The NPI encapsulation process does not compromise viability as measured by OCR/DNA, and ENPI can be cultured for up to 5 weeks with maintenance of viability. ENPI meet or exceed current adult porcine islet product release criteria (established at the University of Minnesota) for preclinical xenotransplantation in terms of OCR/DNA.
There are only so many things that will get a college student motivated enough to wake up at 7:00 on a Saturday morning and walk 5k on an autumn day in Minnesota when it is barely above freezing temep...
Actress Jennifer Esposito, star of CBS' Blue Bloods, is claiming publicly that she has been put on leave from the show because of a misunderstanding of her limitations due to her celiac disease diagnosis.
C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes Published: October 25, 2012
By C8 MediSensors
SAN JOSE, CALIFORNIA, OCTOBER 25, 2012 — /PRNewswire/ --
A new non-invasive continuous glucose monitor is approved for marketing in Europe
C8 MediSensors, Inc. (http://www.c8medisensors.com) has today announced it received CE Mark approval for its Optical Glucose Monitor System, allowing the device, a new non-invasive continuous glucose monitor (nCGM), to be marketed in Europe.
...Corresponding authors: Linda Haas, firstname.lastname@example.org, and Melinda Maryniuk, email@example.com. By the most recent estimates, 18.8 million people in the U.S. have been diagnosed with diabetes and an additional 7 million are believed to be living with undiagnosed diabetes. At the same time, 79 million people are estimated to have blood glucose levels in the range of prediabetes or categories of increased risk for diabetes. Thus, more than 100 million Americans are at risk for developing the devastating complications of diabetes (1).
I super appreciate the work of Firas H. El-Khatib and Ed Damiano et al!
...CONCLUSIONS A bihormonal bionic endocrine pancreas achieved excellent glycemic control with minimal hypoglycemia over the course of two days of continuous use despite high-carbohydrate meals and exercise. A trial testing a wearable version of the system under free-living conditions is justified.
Sports began on American college campuses as a way for students to blow off steam and be healthy....
At Spelman, the wellness initiative includes spending money to help renovate the school's Read Hall, which was built in the 1950s, to make it a state-of-the-art fitness facility, with expanded hours and programs.
"We are trying to meet students where they are in terms of their interest, but also helping them understand that the elements of wellness ... are the kinds of things that are going to help them avoid the kinds of illnesses that are killing African-American women far too early," Tatum said.
My diabetes community was once limited to whom my mom knew or where our car could drive to. And growing up in a small town in America’s smallest state of Rhode Island, my access to others who had diabetes, or who even had a cursory familiarity with it, was scarce. My parents sent me to a special summer camp for kids with diabetes, but those twelve days weren’t enough to make me feel like I was part of a team.
...The compound, a selective chemokine interleukin-8 inhibitor, has shown to improve the efficacy of transplantation of insulin-producing pancreatic islets, which Dompe says is "the new frontier in type 1 diabetes". The Phase III trial will be conducted in 10 centres in Europe and the USA on some 60 patients, which the Milan-headquartered company notes is half the total number of patients undergoing allogeneic pancreatic islet transplantation worldwide....
...Conclusions It seems medically appropriate for all children to use short needles where possible to minimize inadvertent IM injections which may increase glycemic variability. Currently, the safest needle for all children appears to be the 4-mm pen needle. However, when used in children aged 2–6 yr, it should be used with a pinched skin fold.
Recognition for decades spent living with diabetes 29 October 2012 , 10:21 AM by Jacquie Mackay
onclick="window.open( this.href, '_blank', 'width=640,height=480,scrollbars=no,resizable=no,toolbar=no,directories=no,location=no,menubar=no,status=no,left=0,top=0' ); return false" href="http://blogs.abc.net.au/.a/6a00e0097e4e688833017c32e386d9970b-popup">Back in the 1950s when Janet Duncanson and Mervyn Beckett were diagnosed with Type 1 Diabetes as children, they were both incredibly ill and lucky to be diagnosed when they were.
Now some 60 years on for Janet and 54 years on for Mervyn, they look back on the decades they've lived with their chronic disease and appreciate just how much has changed.
On Friday they were both recognised by Diabetes Queensland with Kellion awards for mark their personal triumphs in leading healthy and active lives with the disease.
Michelle Trute the CEO of Diabetes Queensland says sadly though we are seeing many many more people being diagnosed in the area.
FRANKFURT (Reuters) - Bayer AG has called off the sale of its blood glucose meters business for now, Financial Times Deutschland reported, citing industry and financial sources.According to the paper,...
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.